3 ANNEX III COMMON SPECIFICATIONS FOR DEVICES INTENDED FOR DETECTION OR QUANTIFICATION OF MARKERS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION, Regulation (EU) 2022/1107

In forcesince 4 Jul 2022
1.

This Annex applies to devices intended for detection or quantification of markers of human immunodeficiency virus (HIV) infection.

Table 1 applies to first-line assays for HIV-1/2 antibody (anti-HIV-1/2) and first-line combined antigen/antibody assays for HIV-1/2 (HIV-1/2 Ag/Ab) which are not rapid tests.

Table 2 applies to first-line assays for anti-HIV-1/2 and HIV-1/2 Ag/Ab which are rapid tests.

Table 3 applies to confirmatory assays for anti-HIV-1/2.

Table 4 applies to antigen tests for HIV-1 and HIV Ag/Ab assays.

Table 5 applies to qualitative and quantitative NAT devices for HIV ribonucleic acid (RNA).

Table 6 applies to HIV-1/2 self-tests.

2.

For the purposes of this Annex, the following definitions apply:

(1)

‘seroconversion HIV specimen’ means:

p24 antigen and/or HIV RNA positive, and

recognised by the antibody first-line assays, and

positive or indeterminate in confirmatory assays.

(2)

‘early seroconversion HIV specimen’ means:

p24 antigen and/or HIV RNA positive, and

not recognised by the antibody first-line assays, and

indeterminate or negative in confirmatory assays.

[Blood donor populations shall be investigated from at least two blood donation centres and consist of consecutive blood donations, which have not been selected to exclude first-time donors.]

Performance characteristic | Specimen | Specimen numbers, features, use | Acceptance criteria

Diagnostic sensitivity | Positive specimens |

≥400 HIV-1

≥100 HIV-2

including 40 non-B-subtypes

including 25 positive ‘same day’ fresh serum specimens (≤ 1 day after specimen taking)

all available HIV/1 subtypes shall be represented by at least 3 specimens per subtype

all true positive specimens shall be identified as positive

Seroconversion panels |

≥30 panels

at least 40 early seroconversion HIV specimens shall be tested

diagnostic sensitivity during seroconversion shall represent the state of the art

all seroconversion HIV specimens shall be identified as positive

Diagnostic specificity | Unselected blood donors (including first-time donors) | ≥5000 | ≥99,5%

Hospitalised patients | ≥200 | Potential limitations for specificity, if any, shall be identified

Cross-reactivity | Potentially cross-reacting specimens |

≥100 in total

(such as RF+, from related virus infections, from pregnant women, subjects recently vaccinated against any infectious agent)

Performance characteristic | Specimen | Specimen numbers, features, use | Acceptance criteria

Diagnostic sensitivity | Positive specimens |

≥400 HIV-1

≥100 HIV-2

including 40 non-B-subtypes

all available HIV/1 subtypes shall be represented by at least 3 specimens per subtype

all true positive specimens shall be identified as positive

Seroconversion panels |

≥30 panels

at least 40 early seroconversion HIV specimens shall be tested

diagnostic sensitivity during seroconversion shall represent the state of the art

all seroconversion HIV specimens shall be identified as positive

Diagnostic specificity | Unselected blood donors (including first-time donors) | ≥1000 | ≥ 99 %

Hospitalised patients | ≥200 | Potential limitations for specificity, if any, shall be identified

Cross-reactivity | Potentially cross-reacting specimens |

≥200 specimens from pregnant women

≥100 other potentially cross-reacting specimens in total (e.g. RF+, from related infections)

Performance characteristic | Specimen | Specimen numbers, features, use | Acceptance criteria

Diagnostic sensitivity | Positive specimens |

≥200 HIV-1

≥100 HIV-2

Including different stages of infection and reflecting different antibody patterns

Identification as “confirmed positive” or “indeterminate”, not as “negative”

Seroconversion panels |

≥15 seroconversion panels/low titre panels

≥40 early seroconversion HIV specimens

Diagnostic sensitivity during seroconversion shall represent the state of the art

All seroconversion HIV specimens shall be identified as positive

Diagnostic specificity | Blood donors | ≥200 | No false positive results / no neutralisation

Hospitalised patients | ≥200

Cross-reactivity | Potentially cross-reacting specimens | ≥50 in total (including specimens from pregnant women, specimens with indeterminate results in other confirmatory assays)

Performance characteristic | Specimen | Specimen numbers, features, use | Acceptance criteria

Diagnostic sensitivity | Positive specimens |

≥50 HIV-1 antigen positive

≥50 cell culture supernatants including different HIV-1 subtypes and HIV-2

all true positive specimens shall be identified as positive (after neutralisation if applicable)

Seroconversion panels |

≥20 seroconversion panels/low titre panels

≥40 early seroconversion HIV specimens

diagnostic sensitivity during seroconversion shall represent the state of the art

all seroconversion HIV specimens shall be identified as positive

Analytical sensitivity | First International Reference Reagent HIV-1 p24 Antigen, NIBSC code: 90/636 | | ≤ 2 IU/ml

Diagnostic specificity | Blood donors | ≥200 | ≥ 99,5 % after neutralisation or, if no neutralisation test available, after resolution of the specimen status

Hospitalised patients | ≥200 | Potential limitations for specificity, if any, shall be identified

Cross-reactivity | Potentially cross-reacting specimens | ≥50

1.

For target sequence amplification devices, a functionality control for each specimen (internal control) shall reflect the state of the art. This control shall as far as possible be used throughout the whole process, i.e. extraction, amplification/hybridisation, detection.

2.

Genotype and/or subtype detection shall be demonstrated by appropriate primer or probe design validation and shall also be validated by testing characterised genotyped specimens.

3.

Potential cross-reactivity of non-target nucleic acid sequences shall be analysed by appropriate primer or probe design validation and shall also be validated by testing selected specimens.

4.

Results of quantitative NAT devices shall be traceable to international standards or calibrated reference materials, if available, and be expressed in international units utilised in the specific field of application.

5.

Qualitative HIV NAT devices intended to be used to detect the presence of HIV in blood, blood components, cells, tissues or organs, or in any of their derivatives, in order to assess their suitability for transfusion, transplantation or cell administration shall be designed to detect both HIV-1 and HIV-2.

6.

Qualitative HIV NAT devices, other than virus typing devices, shall be designed to compensate for the potential failure of a HIV-1 NAT target region by using two independent target regions.

[Reference: European Pharmacopeia 9.0, 2.6.21 Nucleic acid amplification techniques, Validation.]

Performance characteristic | Specimen | Specimen numbers, features, use | Acceptance criteria

Analytical sensitivity | WHO International Standard HIV-1 RNA; WHO International Standard HIV-2 RNA; or calibrated reference materials |

NAT sensitivity and NAT LOD shall be validated by dilution series of reference materials, testing of replicates (minimum 24) at different analyte concentrations, including those with transition from positive to negative results with the respective NAT device.

LOD shall be expressed as 95% positive cut-off value (IU/ml) after statistical analysis (e.g. Probit).

quantitative NAT: definition of lower, upper quantification limit, precision, accuracy,

‘linear’ measuring range, ‘dynamic range’.

Reproducibility at different concentration levels

According to the state of the art

HIV geno-/subtype sensitivity |

all relevant genotypes/subtypes, preferably from international reference materials

potential substitutes for rare HIV subtypes (to be quantified by appropriate methods): cell culture supernatants; in vitro transcripts; plasmids

Qualitative NAT: at least 10 specimens/genotype or subtype

Quantitative NAT: dilution series for demonstration of quantification efficiencies

According to the state of the art

Diagnostic sensitivity | Positive specimens reflecting the routine conditions of users (e.g. no pre-selection of specimens) |

Quantitative NAT: ≥100

Comparative results with another NAT system shall be generated in parallel

According to the state of the art

Seroconversion panels |

Qualitative NAT: ≥10 panels

Comparative results with another NAT system shall be generated in parallel

According to the state of the art

Diagnostic specificity | Blood donor specimens |

Qualitative NAT: ≥500

Quantitative NAT: ≥100

According to the state of the art

Cross-reactivity | Potentially cross-reacting specimens | ≥10 human retrovirus positive specimens (e.g. HTLV) | According to the state of the art

Carry-over |

High HIV RNA positive;

HIV RNA negative

At least five runs with alternating high-positive and negative specimens shall be performed during robustness studies. The virus titres of the high positive specimens shall be representative of high virus titres occurring naturally. | According to the state of the art

Detection in relation to antibody status | HIV-RNA positives: anti-HIV negative, anti-HIV positive | Pre-seroconversion (anti-HIV negative) and post-seroconversion (anti-HIV positive) specimens | According to the state of the art

Whole system failure rate | HIV RNA low-positive | ≥100 HIV RNA low-positive specimens shall be tested. These specimens shall contain a virus concentration equivalent to three times the 95 % positive cut-off virus concentration. | ≥99% positive

[For each body fluid claimed for use with the device, e.g. whole blood, urine, saliva, etc., the sensitivity and specificity of the device for self-testing in the hands of lay persons shall be defined against the confirmed patient infectious status.] [The result interpretation study shall include reading and interpretation of the test results by at least 100 lay persons, with each lay person subjected to reading results covering the specified range of result reactivity levels. The manufacturer shall determine the concordance between lay person reading and professional user reading.] [Tests shall be performed prior to the result interpretation study using whenever possible the specimen type intended by the manufacturer. The tests may be performed on contrived specimens based on the natural matrix of the respective specimen type.] [A higher proportion of the specimens shall be in the low-positive range close to the cut-off or LOD of the test.]

Performance characteristic | Specimens | Number of lay persons

Result interpretation |

Interpretation of results by lay persons reflecting the following range of reactivity levels:

non-reactive

reactive

weak reactive

invalid

≥ 100

Diagnostic sensitivity | lay persons that are known positive | ≥ 200

Diagnostic specificity | lay persons that do not know their status | ≥ 400

Lay persons that are at high risk of acquiring the infection | ≥ 200